Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: The aim of the present study was to develop, optimizes and evaluate the antiparkinson effects of apigenin loaded phospholipid based nanoemulsion via attenuation of oxidative stress and upregulation of dopamine.
Background: Parkinson’s disease (PD) caused by degeneration of dopaminergic neurons in the substantia nigra, it is linked with the oxidative stress, neuroinflammation and apoptosis. Apigenin (AP) is a flavone enriched in fruits and vegetables, which possess numerous therapeutic actions including anti-apoptotic, anti-inflammatory and free radical scavenging activities.
Method: The antioxidant action was evaluated by 1,1-diphenyl-2-picryl-hydrazyl (DPPH) and reducing power assay, which founds high scavenging efficiency for apigenin loaded phospholipid based nanoemulsion as compared to pure apigenin. The pharmacokinetic parameters and Dopamine concentration were also determined.
Results: The optimized apigenin loaded phospholipid based nanoemulsion was founds drug loading capacity of 12%, entrapment efficiency of 81%, particle size of 60 nm, in vitro drug release (60% in first 6 h), higher cytotoxicity and cellular uptake. The said formulation delivers higher concentration of apigenin to brain via nasal route. Whereas the Biochemical estimation evaluation showed that higher levels of antioxidant enzymes including glutathione, superoxide dismutase and lower level of thiobarbituric acid reactive substances in treated group of rats after receiving of said formulation via intranasal route over haloperidol-induced Parkinson’s disease group (control). The intranasal administration of said formulation founds brain: blood ratio of 3.01>0.097 in 1 h over apigenin solution respectively. Furthermore, it showed direct nose to brain delivery of drug by passing blood brain barrier. Apart from this, the pharmacokinetics of intranasally administered apigenin loaded phospholipid based nanoemulsion showed significantly higher dopamine concentration (19.21 ± 2.06 ng/mL) over haloperidol treated rats (7.21± 1.06 ng/mL).
Conclusion: From the above results, the apigenin loaded phospholipid nanoemulsion might play an important role in the effective management of Parkinsons disease in the near future.
To cite this abstract in AMA style:
M-R. Rahman, V-K. Kumar. Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine. [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/apigenin-loaded-phospholipid-based-nanoemulsion-in-therapeutics-of-parkinsons-disease-via-attenuation-of-oxidative-stress-and-upregulation-of-dopamine/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/apigenin-loaded-phospholipid-based-nanoemulsion-in-therapeutics-of-parkinsons-disease-via-attenuation-of-oxidative-stress-and-upregulation-of-dopamine/